Impatient for Outpatient: Operationalizing Bispecific Antibodies for Multiple Myeloma in the Ambulatory Setting | JCO Oncology Practice
In the article that accompanies this editorial, Sandahl et al 1 describe the successful implementation of an outpatient-based workflow for teclistamab administration. Teclistamab, a bispecific antibody (bsAb) targeting both CD3 on T cells and B-cell maturation antigen (BCMA) on plasma cells, was the first bsAb to receive US Food and Drug Administration (FDA) approval in relapsed/refractory (R/R) multiple myeloma (MM) on the basis of the results of the MajesTEC-1 trial. In updated results from this trial,
